Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MVA Smallpox Vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

NCT02743455
View directory record Official record
Conditions
Yellow Fever, Yellow Fever Immunisation
Interventions
ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ACAM 3000 MVA at Harvard Medical School

NCT00133575
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

NCT03699124
View directory record Official record
Conditions
Smallpox
Interventions
FD MVA-BN
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
1,129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
435 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

NCT01668537
View directory record Official record
Conditions
Smallpox
Interventions
LF formulation of IMVAMUNE®, FD formulation of IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
South Miami, Florida • Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

NCT00857493
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
56 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orlando, Florida • Iowa City, Iowa • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

NCT02038881
View directory record Official record
Conditions
Smallpox
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

NCT00565929
View directory record Official record
Conditions
Variola Major (Smallpox)
Interventions
Placebo, MVA-BN
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 30, 2026, 10:46 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Smallpox Vaccine

NCT00046397
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-M
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 10:46 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells

NCT07199569
View directory record Official record
Conditions
Monkeypox (Mpox)
Interventions
Jynneos, MVA-BN (Quail)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 49 Years
Enrollment
970 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
10
States / cities
Ames, Iowa • Lenexa, Kansas • Rochester, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

NCT00079820
View directory record Official record
Conditions
Smallpox
Interventions
ACAM3000 MVA Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 31 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Lenexa, Kansas • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

NCT00316589
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

MVA Post-Event: Administration Timing and Boost Study

NCT00437021
View directory record Official record
Conditions
Smallpox
Interventions
Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
7
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 30, 2026, 10:46 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS

NCT04957485
View directory record Official record
Conditions
Smallpox
Interventions
Tecovirimat, Smallpox and Mpox Vaccine, Placebo
Drug · Other
Lead sponsor
SIGA Technologies
Industry
Eligibility
18 Years to 42 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Omaha, Nebraska • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive

NCT00282581
View directory record Official record
Conditions
HIV Infections, Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Special Access Program IMVAMUNE®

NCT03472014
View directory record Official record
Conditions
Vaccination
Interventions
IMVAMUNE®
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 30, 2026, 10:46 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Human Immune Response to the JYNNEOS Vaccine

NCT06366672
View directory record Official record
Conditions
Vaccinia, Virus Diseases
Interventions
JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Recruiting Phase 4 Interventional

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

NCT06829238
View directory record Official record
Conditions
Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Interventions
Metformin, Placebo, Jynneos, Capvaxvie
Drug · Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

NCT00914732
View directory record Official record
Conditions
Smallpox
Interventions
MVA Smallpox Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 38 Years
Enrollment
523 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
8
States / cities
Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox

NCT00053742
View directory record Official record
Conditions
Healthy
Interventions
Modified Vaccinia Virus Ankara TBC-MVA
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT00189904
View directory record Official record
Conditions
HIV Infections
Interventions
IMVAMUNE (MVA-BN)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 55 Years
Enrollment
151 participants
Timeline
Started 2005
U.S. locations
5
States / cities
Indianapolis, Indiana • Lexington, Kentucky • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 30, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

NCT05512949
View directory record Official record
Conditions
Monkeypox
Interventions
JYNNEOS
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
8
States / cities
San Diego, California • Washington D.C., District of Columbia • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 10:46 PM EDT